NCT06235918 2024-02-01
Neoadjuvant Tislelizumab Plus Chemotherapy for Resectable Locally-advanced Head and Neck Squamous Cell Carcinoma
Tongji Hospital
Phase 2 Unknown
Clinical Trials
5 trialsNCT05659186 2022-12-21
PD-1 Inhibitor and Anlotinib Combined With Multimodal Radiotherapy in Recurrent or Metastatic Anaplastic Thyroid Cancer
West China Hospital
Phase 2 Unknown
NCT05448885 2022-07-08
Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Unknown
NCT04921995 2022-04-04
RETICULA-NPC
Fudan University
Phase 2 Unknown
NCT04814069 2021-03-24
A Multicenter Phase II Trial of Post-operative Concurrent Chemoradiotherapy Using Weekly Cisplatin With Tislelizumab for Patients With High-risk Head and Neck Squamous Cell Carcinoma：The POTENTIAL Study
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase 2 Unknown